

Maria T Voso

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5345984/maria-t-voso-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

243
papers

6,032
citations

43
h-index

67
g-index

261
ext. papers

7,280
ext. citations

4.8
avg, IF

5.1
L-index

#	Paper	IF	Citations
243	PU.1 (Spi-1) and C/EBP alpha regulate expression of the granulocyte-macrophage colony-stimulating factor receptor alpha gene. <i>Molecular and Cellular Biology</i> , 1995 , 15, 5830-45	4.8	253
242	Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial. <i>Journal of Clinical Oncology</i> , 2016 , 34, 972-9	2.2	228
241	Neutrophils and monocytes express high levels of PU.1 (Spi-1) but not Spi-B. <i>Blood</i> , 1995 , 85, 2918-2928	2.2	202
240	Therapy-related leukemia and myelodysplasia: susceptibility and incidence. <i>Haematologica</i> , 2007 , 92, 1389-98	6.6	163
239	Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3627-3637	2.2	147
238	Inhibition of hematopoiesis by competitive binding of transcription factor PU.1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1994 , 91, 7932-6	11.5	129
237	Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. <i>Nature Medicine</i> , 2020 , 26, 1549-1556	50.5	118
236	Granulocyte colony-stimulating factor promotes the generation of regulatory DC through induction of IL-10 and IFN-alpha. <i>European Journal of Immunology</i> , 2004 , 34, 1291-302	6.1	111
235	Function of PU.1 (Spi-1), C/EBP, and AML1 in early myelopoiesis: regulation of multiple myeloid CSF receptor promoters. <i>Current Topics in Microbiology and Immunology</i> , 1996 , 211, 137-47	3.3	102
234	Therapy related leukemias: susceptibility, prevention and treatment. <i>Leukemia and Lymphoma</i> , 2001 , 41, 255-76	1.9	99
233	Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romo Mielodisplasie Italian Regional Database. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2671-7	2.2	97
232	Negative prognostic value of glutathione S-transferase (GSTM1 and GSTT1) deletions in adult acute myeloid leukemia. <i>Blood</i> , 2002 , 100, 2703-7	2.2	97
231	Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. <i>Lancet Haematology</i> , 2017 , 4, e127-e136	14.6	95
230	Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. <i>Annals of Oncology</i> , 2007 , 18, 346-50	10.3	95
229	Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. <i>Clinical Cancer Research</i> , 2009 , 15, 5002-7	12.9	87
228	Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas. <i>Annals of Oncology</i> , 2009 , 20, 1408-13	10.3	84
227	Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS. <i>Clinical Immunology</i> , 2003 , 109, 89-102	9	84

226	The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma. <i>Clinical Cancer Research</i> , 2011 , 17, 2885-92	12.9	79
225	Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial). <i>European Journal of Haematology</i> , 2014 , 92, 527-36	3.8	76
224	Aberrant methylation of DAP-kinase in therapy-related acute myeloid leukemia and myelodysplastic syndromes. <i>Blood</i> , 2004 , 103, 698-700	2.2	75
223	Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). <i>Lancet Oncology, The</i> , 2008 , 9, 352-8	21.7	73
222	Glutathione S-transferase P1 genotype and prognosis in Hodgkin's lymphoma. <i>Clinical Cancer Research</i> , 2005 , 11, 2175-9	12.9	72
221	In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2000 , 109, 729-35	4.5	72
220	Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2538-43	2.2	70
219	Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine. <i>Leukemia</i> , 2014 , 28, 621-8	10.7	68
218	Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. <i>Blood</i> , 2008 , 112, 3383-90	2.2	68
217	Incidence and susceptibility to therapy-related myeloid neoplasms. <i>Chemico-Biological Interactions</i> , 2010 , 184, 39-45	5	67
216	GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. <i>Blood</i> , 2019 , 134, 935-945	2.2	65
215	Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study. <i>Lancet Oncology, The</i> , 2015 , 16, 1506-1514	21.7	60
214	Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia. <i>British Journal of Cancer</i> , 2006 , 95, 1108-13	8.7	60
213	Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias. <i>American Journal of Hematology</i> , 2015 , 90, E80-5	7.1	59
212	MRD in AML: The Role of New Techniques. <i>Frontiers in Oncology</i> , 2019 , 9, 655	5.3	57
211	PML-RAR β kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy. <i>Leukemia</i> , 2016 , 30, 1987-1992	10.7	57
210	Neutrophils and monocytes express high levels of PU.1 (Spi-1) but not Spi-B. <i>Blood</i> , 1995 , 85, 2918-28	2.2	56
209	Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. <i>Blood</i> , 2020 , 135, 371-380	2.2	53

208	Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination. <i>Oncologist</i> , 2006 , 11, 285-91	5.7	51
207	Increased risk of acute myeloid leukaemia due to polymorphisms in detoxification and DNA repair enzymes. <i>Annals of Oncology</i> , 2007 , 18, 1523-8	10.3	51
206	Immunomagnetic selection of CD34+ peripheral blood stem cells for autografting in patients with breast cancer. <i>British Journal of Haematology</i> , 1997 , 97, 881-8	4.5	49
205	Why methylation is not a marker predictive of response to hypomethylating agents. <i>Haematologica</i> , 2014 , 99, 613-9	6.6	46
204	High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study. <i>Leukemia and Lymphoma</i> , 2013 , 54, 658-61	1.9	45
203	Polymorphisms of CYP1A1 and glutathione S-transferase and susceptibility to adult acute myeloid leukemia. <i>Haematologica</i> , 2004 , 89, 664-70	6.6	45
202	CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha. <i>Blood</i> , 2007 , 110, 3695-705	2.2	44
201	Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma. <i>Annals of Oncology</i> , 2007 , 18, 1376-81	10.3	44
200	Acute Promyelocytic Leukemia: Update on the Mechanisms of Leukemogenesis, Resistance and on Innovative Treatment Strategies. <i>Cancers</i> , 2019 , 11,	6.6	43
199	Association between glutathione S-transferase genotypes and Hodgkin's lymphoma risk and prognosis. <i>Clinical Cancer Research</i> , 2003 , 9, 3435-40	12.9	40
198	Identification of a novel subpopulation of human cord blood CD34-CD133-CD7-CD45+lineage- cells capable of lymphoid/NK cell differentiation after in vitro exposure to IL-15. <i>Journal of Immunology</i> , 2003 , 171, 2977-88	5.3	39
197	Passenger lymphocyte syndrome with severe hemolytic anemia due to an anti-Jk(a) after allogeneic PBPC transplantation. <i>Transfusion</i> , 2000 , 40, 632-6	2.9	39
196	Anemia in diffuse large B-cell non-Hodgkin lymphoma: the role of interleukin-6, hepcidin and erythropoietin. <i>Leukemia and Lymphoma</i> , 2014 , 55, 270-5	1.9	37
195	Outcome of therapy-related myeloid neoplasms treated with azacitidine. <i>Journal of Hematology and Oncology</i> , 2012 , 5, 44	22.4	37
194	Therapy-related myeloid neoplasms. <i>Current Opinion in Oncology</i> , 2011 , 23, 672-80	4.2	37
193	Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2010 , 51, 2275-84	1.9	37
192	Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation (PBSCT). <i>Bone Marrow Transplantation</i> , 2000 , 25, 957-64	4.4	37
191	Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study. <i>Annals of Oncology</i> , 2017 , 28, 1547-1553	10.3	36

190	Autografting with CD34+ peripheral blood stem cells: retained engraftment capability and reduced tumour cell content. <i>British Journal of Haematology</i> , 1999 , 104, 382-91	4.5	36
189	Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. <i>European Journal of Haematology</i> , 2013 , 90, 345-8	3.8	35
188	Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine. <i>Leukemia</i> , 2011 , 25, 1910-3	10.7	35
187	Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias. <i>Current Medicinal Chemistry</i> , 2008 , 15, 1274-87	4.3	35
186	Interleukin-6 plasma levels are modulated by a polymorphism in the NF- κ B1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2012 , 53, 411-6	1.9	33
185	Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes. <i>Neurology</i> , 2011 , 76, 1059-65	6.5	32
184	Prognostic role of glutathione S-transferase polymorphisms in acute myeloid leukemia. <i>Leukemia</i> , 2008 , 22, 1685-91	10.7	32
183	High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro. <i>Oncotarget</i> , 2017 , 8, 32550-32565	3.3	32
182	Preference for involvement in treatment decisions and request for prognostic information in newly diagnosed patients with higher-risk myelodysplastic syndromes. <i>Annals of Oncology</i> , 2014 , 25, 447-54	10.3	31
181	Epigenetic changes in therapy-related MDS/AML. <i>Chemico-Biological Interactions</i> , 2010 , 184, 46-9	5	31
180	Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia. <i>Future Oncology</i> , 2016 , 12, 293-302	3.6	30
179	Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System. <i>Leukemia</i> , 2017 , 31, 2449-2457	10.7	26
178	Impairment of PI3K/AKT and WNT/ β -catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes. <i>Experimental Hematology</i> , 2016 , 44, 75-83.e1-4	3.1	26
177	Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma. <i>Leukemia Research</i> , 2009 , 33, 1352-6	2.7	26
176	Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial. <i>Leukemia</i> , 2020 , 34, 914-918	10.7	26
175	Lack of t(14; 18) Polymerase Chain Reaction-Positive Cells in Highly Purified CD34+ Cells and Their CD19 Subsets in Patients With Follicular Lymphoma. <i>Blood</i> , 1997 , 89, 3763-3768	2.2	25
174	Differential sensitivity of leukemic and normal hematopoietic progenitors to the killing effect of hyperthermia and quercetin used in combination: role of heat-shock protein-70. <i>International Journal of Cancer</i> , 1997 , 73, 75-83	7.5	25
173	Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1223-1233	2.2	25

172	Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms. <i>Blood Cells, Molecules, and Diseases</i> , 2010 , 45, 181-5	2.1	24
171	The growth of primary low-grade B-cell gastric lymphoma is sustained by Helicobacter pylori. <i>Scandinavian Journal of Gastroenterology</i> , 1997 , 32, 285-7	2.4	24
170	Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia. <i>European Journal of Haematology</i> , 2016 , 96, 344-51	3.8	24
169	Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion-dependent anemia and thrombocytopenia. <i>BMC Hematology</i> , 2016 , 16, 12	2.5	24
168	CD68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma. <i>Cancer Medicine</i> , 2016 , 5, 398-406	4.8	24
167	Fanconi anemia gene variants in therapy-related myeloid neoplasms. <i>Blood Cancer Journal</i> , 2015 , 5, e3237		23
166	An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms. <i>Annals of Hematology</i> , 2015 , 94, 771-7	3	22
165	Polymorphisms of detoxification and DNA repair enzymes in myelodysplastic syndromes. <i>Leukemia Research</i> , 2009 , 33, 1068-71	2.7	22
164	Gemtuzumab ozogamicin, cytosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia. <i>Annals of Oncology</i> , 2008 , 19, 128-34	10.3	22
163	Microchimerism in bone marrow-derived CD34+ cells of patients after liver transplantation. <i>Blood</i> , 2000 , 96, 763-767	2.2	22
162	Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes. <i>Leukemia</i> , 2019 , 33, 785-790	10.7	22
161	Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome. <i>Seminars in Hematology</i> , 2018 , 55, 209-214	4	21
160	Impaired bactericidal and fungicidal activities of neutrophils in patients with myelodysplastic syndrome. <i>Leukemia Research</i> , 2012 , 36, 331-3	2.7	21
159	Combined voriconazole plus caspofungin therapy for the treatment of probable Geotrichum pneumonia in a leukemia patient. <i>Infection</i> , 2008 , 36, 65-7	5.8	21
158	Azacitidine for the treatment of retrospective analysis from the Gruppo Laziale for the study of Ph-negative MPN. <i>Leukemia Research</i> , 2015 , 39, 801-4	2.7	20
157	Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases. <i>Leukemia</i> , 2013 , 27, 982-5	10.7	20
156	Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS. <i>Leukemia</i> , 2021 , 35, 835-849	10.7	20
155	Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2017 , 52, 473-475	4.4	19

154	Endothelial progenitor cell dysfunction in myelodysplastic syndromes: possible contribution of a defective vascular niche to myelodysplasia. <i>Neoplasia</i> , 2015 , 17, 401-9	6.4	19
153	Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata. <i>European Journal of Haematology</i> , 2015 , 95, 52-6	3.8	19
152	Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2016 , 57, 628-34	1.9	18
151	The poly(ADP-ribose) polymerase inhibitor olaparib induces up-regulation of death receptors in primary acute myeloid leukemia blasts by NF- κ B activation. <i>Cancer Letters</i> , 2018 , 423, 127-138	9.9	18
150	Incidence of acute myeloid leukemia after breast cancer. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011 , 3, e2011069	3.2	18
149	The small-molecule compound AC-73 targeting CD147 inhibits leukemic cell proliferation, induces autophagy and increases the chemotherapeutic sensitivity of acute myeloid leukemia cells. <i>Haematologica</i> , 2019 , 104, 973-985	6.6	18
148	The BCL2L10 Leu21Arg variant and risk of therapy-related myeloid neoplasms and de novo myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2014 , 55, 1538-43	1.9	17
147	Panobinostat for the treatment of acute myelogenous leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2016 , 25, 1117-31	5.9	17
146	Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study. <i>British Journal of Haematology</i> , 2017 , 177, 741-750	4.5	16
145	Unraveling the mechanisms behind iron overload and ineffective hematopoiesis in myelodysplastic syndromes. <i>Leukemia Research</i> , 2017 , 62, 108-115	2.7	16
144	Epigenetic therapy of myelodysplastic syndromes and acute myeloid leukemia. <i>Current Opinion in Oncology</i> , 2015 , 27, 532-9	4.2	16
143	Quantification of DAPK1 promoter methylation in bone marrow and peripheral blood as a follicular lymphoma biomarker. <i>Journal of Molecular Diagnostics</i> , 2014 , 16, 467-76	5.1	16
142	The dose of granulocyte colony-stimulating factor administered following cytotoxic chemotherapy is not related to the rebound level of circulating CD34+ haemopoietic progenitor cells during marrow recovery. <i>British Journal of Haematology</i> , 1998 , 101, 582-5	4.5	16
141	Prevalence of the 677C to T Mutation in the Methylenetetrahydrofolate Reductase Gene in Italian Patients with Venous Thrombotic Disease. <i>Thrombosis and Haemostasis</i> , 1998 , 79, 686-687	7	16
140	Mutations affecting both the rearranged and the unrearranged PML alleles in refractory acute promyelocytic leukaemia. <i>British Journal of Haematology</i> , 2016 , 172, 909-13	4.5	16
139	In vivo priming with granulocyte colony-stimulating factor possibly enhances the effect of gemtuzumab-ozogamicin in acute myeloid leukemia: results of a pilot study. <i>Haematologica</i> , 2004 , 89, 634-6	6.6	16
138	Minimal residual disease as a biomarker for outcome prediction and therapy optimization in acute myeloid leukemia. <i>Expert Review of Hematology</i> , 2018 , 11, 307-313	2.8	15
137	Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapse. <i>American Journal of Hematology</i> , 2019 , 94, 1091-1097	7.1	15

136	Clonal evolution in therapy-related neoplasms. <i>Oncotarget</i> , 2017 , 8, 12031-12040	3.3	15
135	Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. <i>Leukemia</i> , 2021 , 35, 2539-2551	10.7	15
134	Targeting ADP-ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders. <i>Biochemical Pharmacology</i> , 2019 , 167, 133-148	6	14
133	Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy. <i>Annals of Hematology</i> , 2018 , 97, 1797-1802	3	14
132	SETBP1 mutations in 106 patients with therapy-related myeloid neoplasms. <i>Haematologica</i> , 2014 , 99, e152-3	6.6	14
131	PU.1 and CEBPA expression in acute myeloid leukemia. <i>Leukemia Research</i> , 2008 , 32, 1448-53	2.7	14
130	PML/RARa inhibits PTEN expression in hematopoietic cells by competing with PU.1 transcriptional activity. <i>Oncotarget</i> , 2016 , 7, 66386-66397	3.3	14
129	Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016 , 8, e2016052	3.2	14
128	Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy. <i>BMJ Supportive and Palliative Care</i> , 2016 , 6, 80-8	2.2	13
127	Two promoters direct expression of the murine Spi-B gene, an Ets family transcription factor. <i>Gene</i> , 1998 , 207, 209-18	3.8	13
126	Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. <i>Blood Advances</i> , 2020 , 4, 4945-4954	7.8	13
125	Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes. <i>Leukemia Research</i> , 2015 , 39, 859-65	2.7	12
124	Comparative molecular analysis of therapy-related and de novo acute promyelocytic leukemia. <i>Leukemia Research</i> , 2012 , 36, 474-8	2.7	12
123	Atypical presentation of progressive multifocal leukoencephalopathy in a multiple myeloma patient after auto-SCT successfully treated with combination therapy. <i>Bone Marrow Transplantation</i> , 2010 , 45, 1668-70	4.4	12
122	Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma). <i>Annals of Oncology</i> , 2012 , 23, 805-807	10.3	12
121	Glutathione-S-transferase genotypes influence prognosis in follicular non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 2007 , 48, 564-9	1.9	12
120	Treatment of acute leukaemias with monoclonal antibodies: current status and future prospects. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2006 , 4, 33-52	1.9	12
119	When Poisons Cure: The Case of Arsenic in Acute Promyelocytic Leukemia. <i>Chemotherapy</i> , 2019 , 64, 238-247	3.47	12

118	Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine. <i>Leukemia Research</i> , 2011 , 35, 465-71	2.7	11
117	Identification and monitoring of atypical PML/RARA fusion transcripts in acute promyelocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2019 , 58, 60-65	5	11
116	Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors. <i>Hematological Oncology</i> , 2019 , 37, 291-295	1.3	10
115	High-dose therapy with peripheral blood stem cell transplantation results in a significant reduction of the haemopoietic progenitor cell compartment. <i>British Journal of Haematology</i> , 1996 , 94, 759-66	4.5	10
114	Retinoic acid synergizes with the unfolded protein response and oxidative stress to induce cell death in FLT3-ITD+ AML. <i>Blood Advances</i> , 2019 , 3, 4155-4160	7.8	10
113	Early and sensitive detection of PML-A216V mutation by droplet digital PCR in ATO-resistant acute promyelocytic leukemia. <i>Leukemia</i> , 2019 , 33, 1527-1530	10.7	10
112	Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations. <i>Blood Reviews</i> , 2019 , 34, 16-25	11.1	10
111	DAP-kinase hypermethylation in the bone marrow of patients with follicular lymphoma. <i>Haematologica</i> , 2006 , 91, 1252-6	6.6	10
110	The Role of Forkhead Box Proteins in Acute Myeloid Leukemia. <i>Cancers</i> , 2019 , 11,	6.6	9
109	Rapid response of nodular CD30-positive mycosis fungoides to brentuximab vedotin. <i>British Journal of Haematology</i> , 2015 , 168, 617	4.5	9
108	Essential Thrombocythemia and Acquired von Willebrand Syndrome: The Shadowlands between Thrombosis and Bleeding. <i>Cancers</i> , 2020 , 12,	6.6	9
107	Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia. <i>Annals of Hematology</i> , 2018 , 97, 1767-1774	3	9
106	Therapy-related myeloid neoplasms: clinical perspectives. <i>OncoTargets and Therapy</i> , 2018 , 11, 5909-5915	4.4	9
105	Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes. <i>Cancers</i> , 2019 , 11,	6.6	8
104	Four doses of unpegylated versus one dose of pegylated filgrastim as supportive therapy in R-CHOP-14 for elderly patients with diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2015 , 169, 787-94	4.5	8
103	From Bench to Bedside and Beyond: Therapeutic Scenario in Acute Myeloid Leukemia. <i>Cancers</i> , 2020 , 12,	6.6	7
102	Myelodysplastic disorders carrying both isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapy. <i>OncoTargets and Therapy</i> , 2014 , 7, 1043-50	4.4	7
101	Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine. <i>Leukemia and Lymphoma</i> , 2013 , 54, 1786-7	1.9	7

100	Primary plasma cell leukemia followed by testicular plasmacytoma. <i>International Journal of Hematology</i> , 2011 , 93, 224-227	2.3	7
99	Efficacy of combined surgery and antifungal therapies for the management of invasive zygomycoses in patients with haematological malignancies. <i>Mycoses</i> , 2010 , 53, 89-92	5.2	7
98	Baseline T-lymphocyte subset absolute counts can predict both outcome and severity in SARS-CoV-2 infected patients: a single center study. <i>Scientific Reports</i> , 2021 , 11, 12762	4.9	7
97	Early intracranial haemorrhages in acute promyelocytic leukaemia: analysis of neuroradiological and clinico-biological parameters. <i>British Journal of Haematology</i> , 2021 , 193, 129-132	4.5	7
96	Longitudinal detection of DNMT3A transcripts in patients with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018 , 93, E120-E123	7.1	6
95	Similarities and differences between therapy-related and elderly acute myeloid leukemia. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011 , 3, e2011052	3.2	6
94	Acute myeloid leukemia in elderly patients aged over 75 years: experience of a single centre. <i>Leukemia and Lymphoma</i> , 2003 , 44, 1441-3	1.9	6
93	Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter study. <i>Annals of Hematology</i> , 2016 , 95, 1059-65	3	6
92	Chronic myelomonocytic leukemia treatment with azacitidine: what have we learned so far?. <i>Leukemia Research</i> , 2013 , 37, 204-5	2.7	5
91	Prevalence of obesity in young adults with acute lymphoblastic leukemia. <i>International Journal of Clinical and Laboratory Research</i> , 1994 , 24, 117-9		5
90	Oral azacitidine prolongs survival of patients with AML in remission independent of measurable residual disease status.. <i>Blood</i> , 2022 ,	2.2	5
89	PML/RARa Interferes with NRF2 Transcriptional Activity Increasing the Sensitivity to Ascorbate of Acute Promyelocytic Leukemia Cells. <i>Cancers</i> , 2019 , 12,	6.6	5
88	PML/RARA inhibits expression of HSP90 and its target AKT. <i>British Journal of Haematology</i> , 2019 , 184, 937-948	4.5	5
87	Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. <i>Cells</i> , 2020 , 9,	7.9	4
86	Iron overload alters the energy metabolism in patients with myelodysplastic syndromes: results from the multicenter FISM BIOFER study. <i>Scientific Reports</i> , 2020 , 10, 9156	4.9	4
85	The forkhead box C1 (FOXC1) transcription factor is downregulated in acute promyelocytic leukemia. <i>Oncotarget</i> , 2017 , 8, 84074-84085	3.3	4
84	Methylenetetrahydrofolate reductase polymorphisms in myelodysplastic syndromes and therapy-related myeloid neoplasms. <i>Leukemia and Lymphoma</i> , 2014 , 55, 2942-4	1.9	4
83	5-azacytidine in chronic myelomonocytic leukemia: case report and review of literature. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011 , 3, e2011011	3.2	4

82	Response to 5-azacytidine in a patient with relapsed Hodgkin Lymphoma and a therapy-related myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2011 , 154, 141-3	4.5	4
81	New treatments for myelodysplastic syndromes. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2010 , 2, e2010021	3.2	4
80	High-dose therapy with peripheral blood stem cell transplantation for patients with relapsed or refractory Hodgkin's disease: long-term outcome and prognostic factors. <i>Annals of Hematology</i> , 2000 , 79, 547-55	3	4
79	Adjuvant high-dose therapy with peripheral blood stem cell support for patients with high-risk breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1999 , 44 Suppl, S13-7	3.5	4
78	Azacitidine and Durvalumab in First-line Treatment of Elderly Patients With Acute Myeloid Leukemia.. <i>Blood Advances</i> , 2021 ,	7.8	4
77	A Phase II Trial of FM (Oral Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin [®]) for Previously Untreated Follicular Lymphoma (FL) Patients.. <i>Blood</i> , 2006 , 108, 2479-2479	2.2	4
76	Iron in Hodgkin's lymphoma. <i>Critical Reviews in Oncogenesis</i> , 2013 , 18, 463-9	1.3	4
75	Prevalence of Mutated Factor V ARG506 to GLN in Italians. <i>Thrombosis and Haemostasis</i> , 1997 , 77, 216-217		4
74	Characterization of FLT3-ITD acute myeloid leukemia: molecular profiling of leukemic precursor cells. <i>Blood Cancer Journal</i> , 2020 , 10, 85	7	4
73	Poly(ADP-Ribose) Polymerase Inhibitors for Arsenic Trioxide-Resistant Acute Promyelocytic Leukemia: Synergistic In Vitro Antitumor Effects with Hypomethylating Agents or High-Dose Vitamin C. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021 , 377, 385-397	4.7	4
72	Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. <i>Leukemia</i> , 2021 ,	10.7	4
71	Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study. <i>Annals of Hematology</i> , 2014 , 93, 1413-20	3	3
70	Azacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing schedule. <i>Leukemia Research</i> , 2012 , 36, e15-7	2.7	3
69	Role of glutathione-S-transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial. <i>Leukemia and Lymphoma</i> , 2012 , 53, 406-10	1.9	3
68	Small lymphocytic lymphoma in a patient with Fabry disease. <i>Leukemia and Lymphoma</i> , 2013 , 54, 184-5	1.9	3
67	Disappearance of spontaneous erythroid colonies in patients with myeloproliferative disorders treated by alpha-interferon. <i>British Journal of Haematology</i> , 1992 , 81, 310-1	4.5	3
66	Blastoid mantle cell lymphoma occurring in a patient in complete remission of chronic myelogenous leukemia. <i>Laboratory Hematology: Official Publication of the International Society for Laboratory Hematology</i> , 2007 , 13, 30-3		3
65	Acute Promyelocytic Leukemia: Update on the Mechanisms of Leukemogenesis, Resistance and on Innovative Treatment Strategies		3

64	Myeloid lncRNA LOUP mediates opposing regulatory effects of RUNX1 and RUNX1-ETO in t(8;21) AML. <i>Blood</i> , 2021 , 138, 1331-1344	2.2	3
63	Mutational profile and haematological response to iron chelation in myelodysplastic syndromes (MDS). <i>British Journal of Haematology</i> , 2019 , 185, 954-957	4.5	3
62	Transcription factors implicated in late megakaryopoiesis as markers of outcome after azacitidine and allogeneic stem cell transplantation in myelodysplastic syndrome. <i>Leukemia Research</i> , 2019 , 84, 1061-1071	2.7	2
61	Real-life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile. <i>American Journal of Hematology</i> , 2014 , 89, 565	7.1	2
60	Mutational analysis of bone marrow mesenchymal stromal cells in myeloid malignancies. <i>Experimental Hematology</i> , 2014 , 42, 731-3	3.1	2
59	Genomic analysis of therapy-related acute promyelocytic leukemias arising after malignant and non-malignant disorders. <i>American Journal of Hematology</i> , 2014 , 89, 346-7	7.1	2
58	Profile of azacitidine. <i>Therapy: Open Access in Clinical Medicine</i> , 2005 , 2, 717-731		2
57	L-Asparaginase-Induced Coagulopathy in Acute Lymphoblastic Leukemia. <i>Leukemia and Lymphoma</i> , 1992 , 7, 54-56	1.9	2
56	Polymorphism in Cytokine Genes as Prognostic Marker in Hodgkin Lymphoma.. <i>Blood</i> , 2005 , 106, 21-21	2.2	2
55	Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. <i>Nature Communications</i> , 2021 , 12, 6233	17.4	2
54	Terminal deoxynucleotidyl transferase (TdT) expression is associated with FLT3-ITD mutations in Acute Myeloid Leukemia. <i>Leukemia Research</i> , 2020 , 99, 106462	2.7	2
53	Use of Measurable Residual Disease to Evolve Transplant Policy in Acute Myeloid Leukemia: A 20-Year Monocentric Observation. <i>Cancers</i> , 2021 , 13,	6.6	2
52	What's new in the pathogenesis and treatment of therapy-related myeloid neoplasms. <i>Blood</i> , 2021 , 138, 749-757	2.2	2
51	Mutational profile of ZBTB16-RARA-positive acute myeloid leukemia. <i>Cancer Medicine</i> , 2021 , 10, 3839-3848	4.7	2
50	A Population-Based Study on Myelodysplastic Syndromes in the Lazio Region (Italy), Medical Miscoding and 11-Year Mortality Follow-Up: the Gruppo Romano-Laziale Mielodisplasie Experience of Retrospective Multicentric Registry. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> 2017 , 9, e2017045	3.2	2
49	Molecular Expression of Bone Marrow Angiogenic Factors, Cell-Cell Adhesion Molecules and Matrix-Metallo-Proteinases in Plasmacellular Disorders: a Molecular Panel to Investigate Disease Progression. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2018 , 10, e2018059	3.2	2
48	Acute Promyelocytic Leukemia in Children: A Model of Precision Medicine and Chemotherapy-Free Therapy. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	2
47	Have we reached a molecular era in myelodysplastic syndromes?. <i>Hematology American Society of Hematology Education Program</i> , 2021 , 2021, 418-427	3.1	2

46	Ascorbate Plus Buformin in AML: A Metabolic Targeted Treatment. <i>Cancers</i> , 2022 , 14, 2565	6.6	2
45	Could haemochromatosis (HFE) gene mutations affect response to iron chelation in myelodysplastic syndrome? - Response to Lucijanac and Kusec. <i>British Journal of Haematology</i> , 2019 , 186, 639-640	4.5	1
44	Genetic analysis of erythrocytosis reveals possible causative and modifier gene mutations. <i>British Journal of Haematology</i> , 2019 , 186, e100-e103	4.5	1
43	Development of a high-resolution melting curve analysis screening test for SRSF2 splicing factor gene mutations in myelodysplastic syndromes. <i>Journal of Molecular Diagnostics</i> , 2015 , 17, 85-9	5.1	1
42	Comparative genomic analysis of PML and RARA breakpoints in paired diagnosis/relapse samples of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. <i>Leukemia and Lymphoma</i> , 2018 , 59, 1268-1270	1.9	1
41	Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome after bupropion treatment for smoking cessation. <i>Blood Coagulation and Fibrinolysis</i> , 2003 , 14, 77-8	1	1
40	The Genomic Landscape of Myeloid Neoplasms Evolved from AA/PNH. <i>Blood</i> , 2020 , 136, 2-2	2.2	1
39	Clonal Hematopoiesis Is Associated with Increased Risk for Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia Patients Treated with Chemo(immuno)Therapy. <i>Blood</i> , 2020 , 136, 19-20	2.2	1
38	Gentuzumab-Ozogamicin,Cytosine Arabinoside, G-CSF Combination in the Treatment of Elderly Poor Prognosis Acute Myeloid Leukemia. A Multicentric Study.. <i>Blood</i> , 2005 , 106, 4604-4604	2.2	1
37	Lack of t(14; 18) Polymerase Chain Reaction-Positive Cells in Highly Purified CD34+ Cells and Their CD19 Subsets in Patients With Follicular Lymphoma. <i>Blood</i> , 1997 , 89, 3763-3768	2.2	1
36	Demethylation and upregulation of an oncogene post hypomethylating treatment		1
35	Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants. <i>Blood Cancer Journal</i> , 2021 , 11, 167	7	1
34	Profile of azacitidine. <i>Therapy: Open Access in Clinical Medicine</i> , 2005 , 2, 717-731		1
33	Mobilization and Selection of CD 34+ Cells. <i>Recent Results in Cancer Research</i> , 1998 , 1-7	1.5	1
32	5-Azacitidine, Valproic Acid and ALL-Trans Retinoic Acid in INT-2/High Risk Myelodysplastic Syndromes: Results of the GIMEMA MDS0205 Multicenter Trial. <i>Blood</i> , 2008 , 112, 3648-3648	2.2	1
31	Pulmonary infections in patients with myelodysplastic syndromes receiving frontline azacytidine treatment. <i>Hematological Oncology</i> , 2020 , 38, 189-196	1.3	1
30	Absence of FGFR3-TACC3 rearrangement in hematological malignancies with numerical chromosomal alteration. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021 , 14, 163-168	2.7	1
29	From Clonal Hematopoiesis to Therapy-Related Myeloid Neoplasms: The Silent Way of Cancer Progression. <i>Biology</i> , 2021 , 10,	4.9	1

28	MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine. <i>Pharmacogenomics Journal</i> , 2018 , 18, 444-449	3.5	1
27	A Relapsing Meningeal Acute Myeloid Leukaemia FLT3-ITD+ Responding to Gilteritinib. <i>Chemotherapy</i> , 2021 , 66, 134-138	3.2	1
26	Long-term quality of life of patients with acute promyelocytic leukemia treated with arsenic trioxide vs chemotherapy. <i>Blood Advances</i> , 2021 , 5, 4370-4379	7.8	1
25	Lack of t(14;18) polymerase chain reaction-positive cells in highly purified CD34+ cells and their CD19 subsets in patients with follicular lymphoma. <i>Blood</i> , 1997 , 89, 3763-8	2.2	1
24	Atypical Rearrangements in APL-Like Acute Myeloid Leukemias: Molecular Characterization and Prognosis.. <i>Frontiers in Oncology</i> , 2022 , 12, 871590	5.3	1
23	High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity. <i>International Journal of Hematology</i> , 2020 , 112, 141-146	2.3	0
22	Acute Promyelocytic Leukemia After Radium-223 Exposure for Prostate Cancer in a Chemotherapy-Naïve Patient. <i>Nuclear Medicine and Molecular Imaging</i> , 2020 , 54, 256-260	1.9	0
21	Erythropoietin levels and erythroid differentiation parameters in patients with lower-risk myelodysplastic syndromes. <i>Leukemia Research</i> , 2018 , 71, 89-91	2.7	0
20	Second malignancy after treatment of adult acute myeloid leukemia: cohort study on adult patients enrolled in the GIMEMA trials. <i>Leukemia</i> , 2004 , 18, 651-3	10.7	0
19	CD34 + CD38-CLL1+ leukemic stem cells persistence measured by multiparametric flow cytometry is a biomarker of poor prognosis in adult patients with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021 , 1-5	1.9	0
18	WT1 evaluation in higher-risk myelodysplastic syndrome patients treated with azacitidine. <i>Leukemia and Lymphoma</i> , 2020 , 61, 979-982	1.9	0
17	Diagnosis and Classification of AML: WHO 2016. <i>Hematologic Malignancies</i> , 2021 , 23-54	0	0
16	Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols. <i>Acta Oncologica</i> , 2021 , 60, 1520-1526	3.2	0
15	An abnormal secretion of soluble mediators contributes to the hematopoietic-niche dysfunction in low-risk myelodysplastic syndrome. <i>Blood Cancer Journal</i> , 2015 , 5, e370	7	
14	Myelodysplastic Stem Cells: Gene Expression Profiling. <i>Stem Cells and Cancer Stem Cells</i> , 2012 , 55-67		
13	Reply to S. Zucker. <i>Journal of Clinical Oncology</i> , 2011 , 29, e43-e43	2.2	
12	Hepato-splenic mycotic abscesses in patients with acute leukemia. <i>Leukemia and Lymphoma</i> , 1992 , 7, 517-9	1.9	
11	Azacitidine to Consolidate and Deepen the Therapeutic Response Achieved by Intensive Induction Treatment in a Young Patient Affected by NPM1mut-AML Who Has Become Ineligible for High-Dose Consolidation.. <i>Chemotherapy</i> , 2022 , 1-5	3.2	

- 10 Does RAD21 Co-Mutation Have a Role in DNMT3A Mutated AML? Results of Harmony Alliance AML Database. *Blood*, **2021**, 138, 608-608 2.2
- 9 Quantitation of EBV-DNA In Peripheral Blood In Hodgkin Lymphoma: Associations with Other Biomarkers and Patient Characteristics. *Blood*, **2010**, 116, 2678-2678 2.2
- 8 Health-Related Quality of Life Profile and Request of Prognostic Information on Survival At the Time of Diagnosis in Patients with High-Risk Myelodysplastic Syndromes. *Blood*, **2011**, 118, 2078-2078 2.2
- 7 Response to Erythropoietin in a Multicentric Real-Life Cohort of Myelodysplastic Patients: The Grom Experience. *Blood*, **2012**, 120, 4958-4958 2.2
- 6 The Contact with MDS Endothelial Cells Alters the Pattern of Lineage-Specific Gene Expression During Normal Hematopoietic Differentiation. *Blood*, **2012**, 120, 1718-1718 2.2
- 5 Azacitidine in Myelodysplastic Syndromes: Multicenter Retrospective Study of 34 Long-Responder Patients. *Blood*, **2012**, 120, 4951-4951 2.2
- 4 Patient-Reported Fatigue, Functional Aspects and Quality of Life in Elderly Patients with High-Risk Myelodysplastic Syndromes. Evidence From a Large Prospective International Study.. *Blood*, **2012**, 120, 3163-3163 2.2
- 3 Real-Life Efficacy Of Azacitidine In Myelodysplastic Syndromes According To IPSS Cytogenetic Profile. *Blood*, **2013**, 122, 5229-5229 2.2
- 2 Prognostic Factors Associated To Achievement Of Complete Or Partial Response In MDS Patients Treated With Azacitidine Outside Clinical Trials. *Blood*, **2013**, 122, 5203-5203 2.2
- 1 Diagnostic Workup of Acute Myeloid Leukemia: What Is Really Necessary? An Italian Survey.. *Frontiers in Oncology*, **2022**, 12, 828072 5.3